[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Exelixis Inc (EXEL)

Exelixis Inc (EXEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,590,765
  • Shares Outstanding, K 251,355
  • Annual Sales, $ 2,320 M
  • Annual Income, $ 782,570 K
  • EBIT $ 937 M
  • EBITDA $ 966 M
  • 60-Month Beta 0.44
  • Price/Sales 5.66
  • Price/Cash Flow 17.24
  • Price/Book 7.12

Options Overview Details

View History
  • Implied Volatility 31.86% (-5.24%)
  • Historical Volatility 39.06%
  • IV Percentile 11%
  • IV Rank 11.60%
  • IV High 71.05% on 10/17/25
  • IV Low 26.71% on 08/28/25
  • Expected Move (DTE 12) 2.47 (4.56%)
  • Put/Call Vol Ratio 0.28
  • Today's Volume 1,668
  • Volume Avg (30-Day) 1,248
  • Put/Call OI Ratio 1.35
  • Today's Open Interest 49,673
  • Open Int (30-Day) 40,071
  • Expected Range 51.61 to 56.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $0.78
  • Number of Estimates 5
  • High Estimate $0.83
  • Low Estimate $0.66
  • Prior Year $0.67
  • Growth Rate Est. (year over year) +16.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
51.76 +4.46%
on 08/06/26
57.42 -5.83%
on 07/09/26
-3.01 (-5.27%)
since 07/07/26
3-Month
46.46 +16.38%
on 05/08/26
57.57 -6.08%
on 07/07/26
+7.86 (+17.01%)
since 05/07/26
52-Week
33.76 +60.18%
on 10/20/25
57.57 -6.08%
on 07/07/26
+16.68 (+44.61%)
since 08/07/25

Most Recent Stories

More News
Exelixis: Q2 Earnings Snapshot

Exelixis: Q2 Earnings Snapshot

EXEL : 54.07 (+3.58%)
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

- Total Revenues of $628.7 million, Cabozantinib Franchise U.S. Net Product Revenues of $573.0 million - - GAAP Diluted...

EXEL : 54.07 (+3.58%)
Can Exelixis Explain Why the Pipeline Matters More Than the Product Everyone's Waiting For?

Barchart Research What to Expect from EXEL Earnings EXEL Generated August 4, 2026 Current Price $56.01 EPS Estimate $$0.75 Consensus Rating Moderate Buy Average Move 9.99% Can Exelixis Explain Why the...

EXEL : 54.07 (+3.58%)
Exelixis: When Your Entire Valuation Rides on One Pipeline Readout

Barchart Research What to Expect from EXEL Earnings EXEL Generated July 24, 2026 Current Price $55.37 EPS Estimate $$0.75 Consensus Rating Moderate Buy Average Move 9.99% Exelixis: When Your Entire Valuation...

EXEL : 54.07 (+3.58%)
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT –

EXEL : 54.07 (+3.58%)
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer

Exelixis, Inc. (Nasdaq: EXEL) today announced results from the final analysis of the dual primary endpoint of overall survival (OS) in the subset of patients without active liver metastases (non-liver...

EXEL : 54.07 (+3.58%)
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026

– CABOMETYX significantly reduced the risk of disease progression or death by 74% and 60% in patients with non-functional and functional advanced NET, respectively, versus placebo –

EXEL : 54.07 (+3.58%)
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June

- Presentations to be webcast on www.exelixis.com -

EXEL : 54.07 (+3.58%)
Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near

Exelixis (NASDAQ:EXEL) remains focused on expanding its CABO franchise while preparing for potential launches and data readouts tied to zanzalintinib, Andrew Peters, the company’s senior vice president...

EXEL : 54.07 (+3.58%)
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types

– Findings in neuroendocrine tumors, kidney cancer, advanced colorectal cancer and other tumors to be presented –

EXEL : 54.07 (+3.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the...

See More

Key Turning Points

3rd Resistance Point 56.72
2nd Resistance Point 55.43
1st Resistance Point 54.75
Last Price 54.07
1st Support Level 52.78
2nd Support Level 51.49
3rd Support Level 50.81

See More

52-Week High 57.57
Last Price 54.07
Fibonacci 61.8% 48.47
Fibonacci 50% 45.66
Fibonacci 38.2% 42.85
52-Week Low 33.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.